Restrictive cardiomyopathy (RCM) is a condition where the walls of the heart’s lower chambers become stiff and can’t relax properly between beats. The heart still squeezes with reasonable force, but it can’t fill with enough blood during the resting phase of each heartbeat. This leads to a backup of blood in the lungs and body, producing symptoms of heart failure. It’s the least common type of cardiomyopathy and often carries a serious prognosis, with five-year survival rates around 66% even after heart transplantation.
How It Affects the Heart
In a healthy heart, the ventricles (lower chambers) expand easily between contractions, allowing blood to flow in from the upper chambers. In restrictive cardiomyopathy, the ventricle walls lose that flexibility. They become rigid, so blood backs up into the upper chambers, then into the lungs and veins throughout the body. The heart’s pumping power often remains normal or near-normal for a while, which is what distinguishes RCM from other forms of heart failure where the muscle weakens and can’t squeeze effectively.
The stiffness happens through one of four basic mechanisms. The heart muscle itself can become scarred with fibrous tissue. Abnormal proteins or other substances can infiltrate the spaces between heart muscle cells. Storage material can accumulate inside the cells themselves. Or the inner lining of the heart can thicken and stiffen. Which mechanism is at work determines both the underlying cause and how the disease is treated.
Common and Rare Causes
Amyloidosis is the most common infiltrative cause. In this disease, misfolded proteins deposit between heart muscle cells, gradually making the walls thicker and stiffer. Several types exist: one is related to abnormal antibody proteins (AL amyloidosis), while others involve a transport protein called transthyretin that misfolds either due to a genetic mutation or simply with aging.
Sarcoidosis, an inflammatory condition that forms tiny clusters of immune cells in various organs, can also infiltrate the heart and produce restrictive physiology. Iron overload (hemochromatosis), whether inherited or from repeated blood transfusions, causes iron to accumulate inside heart muscle cells. Anderson-Fabry disease, Danon disease, and several glycogen storage disorders work similarly, filling cells with material they can’t break down.
Other causes include radiation therapy to the chest, scleroderma, carcinoid syndrome, and certain medications like anthracycline chemotherapy drugs or ergotamine. Tropical endomyocardial fibrosis, which thickens the inner lining of the heart, is an important cause in parts of Africa and South America. A condition called hypereosinophilic syndrome (formerly Loeffler endocarditis) damages the heart lining through an overactive immune response. In some cases, no underlying cause is found, and the diagnosis is considered idiopathic.
Genetic Forms
Familial restrictive cardiomyopathy can be inherited. Mutations in the TNNI3 gene are one of the major genetic causes. This gene provides instructions for making cardiac troponin I, a protein found only in the heart that helps regulate how the muscle contracts and relaxes. When the protein is defective, the heart muscle doesn’t relax normally between beats. Mutations in other genes, including MYH7, TNNT2, and DES, account for smaller numbers of familial cases.
Symptoms to Recognize
The earliest symptom is usually exercise intolerance. When your heart rate rises during activity, there’s even less time for the stiff ventricles to fill, so cardiac output drops and you feel exhausted or short of breath with minimal effort. Over time, shortness of breath worsens and can occur even at rest, while lying flat, or wake you from sleep.
As the right side of the heart becomes involved, fluid backs up into the body rather than the lungs. This causes swelling in the legs and ankles, pain in the upper right abdomen (from a swollen liver), and a buildup of fluid in the belly. Some people also experience chest pain, fainting, or heart palpitations. In advanced disease, malnutrition, significant weight loss, and declining kidney and liver function can develop. Many patients also show signs of whatever systemic disease is driving the restriction, which can help point toward a diagnosis.
How It’s Diagnosed
Echocardiography (heart ultrasound) is the primary tool. In advanced RCM, it reveals a characteristic pattern: blood rushes into the ventricle very quickly at first, then filling stops abruptly because the stiff walls can’t stretch further. Specific measurements help confirm this. The E/A ratio, which compares early and late filling velocities, typically exceeds 2.5. The deceleration time of early filling drops below 140 to 150 milliseconds, meaning the ventricle fills and stops abnormally fast. The walls of the ventricle relax so poorly that tissue velocities at the base of the heart fall to just 3 to 4 centimeters per second.
Cardiac MRI adds another layer of detail. When a contrast agent called gadolinium is injected, different patterns of enhancement can point toward specific causes. A diffuse, powdery enhancement pattern throughout the left ventricle suggests amyloidosis. Enhancement concentrated in the inner lining near the tip of the heart, sometimes with obliteration of the ventricular tip, points toward endomyocardial fibrosis. The ventricular septum (the wall between the two lower chambers) is the most commonly affected segment.
Blood tests, genetic testing, and sometimes heart biopsy may be needed to identify the specific underlying disease.
Telling It Apart From Constrictive Pericarditis
Constrictive pericarditis, where the sac surrounding the heart becomes thick and rigid, can look almost identical to RCM on initial evaluation. Both cause the same backup of blood and similar symptoms. But the distinction matters enormously because constrictive pericarditis is often surgically curable, while RCM generally is not.
The key difference shows up during breathing. In constrictive pericarditis, blood flow across the heart valves changes dramatically with each breath in and out. These swings are absent in RCM. Additionally, patients with RCM are more likely to have backward leakage through the heart’s valves during the filling phase. Imaging with CT or MRI can also reveal a thickened pericardium in constrictive disease, which is absent in RCM.
Treatment Options
There is no single treatment that reverses the stiffness in most forms of RCM. The approach has two parts: managing the heart failure symptoms and, when possible, treating the underlying disease causing the restriction.
Diuretics (water pills) are the mainstay for reducing fluid buildup. However, managing fluid balance in RCM is a delicate act. The stiff ventricles need higher-than-normal filling pressures to push blood through, so removing too much fluid can actually make things worse by reducing blood flow to the organs. Medications that slow the heart rate, like beta-blockers or calcium channel blockers, are sometimes used to give the ventricles more time to fill or to control irregular heart rhythms, but some patients can’t tolerate them. Blood pressure medications that relax blood vessels may be tried but lack strong evidence of benefit in RCM specifically.
Blood thinners are important for patients who develop atrial fibrillation, blood clots in the heart, or evidence of clots traveling to other parts of the body. Even without these complications, the sluggish blood flow in RCM’s enlarged upper chambers creates a tendency toward clot formation.
Treating the underlying cause can sometimes slow or halt disease progression. For amyloidosis, newer therapies targeting the abnormal proteins have changed the outlook considerably. Iron removal therapy helps in hemochromatosis. Enzyme replacement can address some storage diseases. For causes like radiation damage or idiopathic fibrosis, there is no disease-specific treatment.
Heart Transplantation
For patients with advanced, refractory symptoms, heart transplantation may be considered. One-year survival after transplant for RCM patients is about 84%, and five-year survival is around 66%, which is only slightly lower than transplant outcomes for other conditions. However, certain subtypes fare much worse. Patients with amyloidosis or prior radiation therapy have five-year post-transplant survival of just 47%.
Amyloidosis presents a particular challenge because the disease can recur in the transplanted heart. Patients with AL amyloidosis who achieve a complete response to chemotherapy after transplant survive a median of nearly 11 years, while those who don’t respond survive only about one year. For this reason, a combined strategy of heart transplant followed by aggressive amyloid-directed therapy is typically used.
Mechanical heart pumps (ventricular assist devices) are sometimes used as a bridge in end-stage heart failure, but the small, stiff ventricle chambers in RCM make implantation technically difficult. Their use is generally limited to patients without significant disease outside the heart.
Living With Restrictive Cardiomyopathy
RCM tends to progress over time, though the pace varies enormously depending on the cause. Idiopathic and some genetic forms may remain stable for years. Amyloidosis, particularly the AL type, can progress rapidly without targeted treatment. Monitoring typically involves regular echocardiograms to track changes in heart function and filling patterns, along with blood work to check for organ damage from fluid overload or the underlying disease. Careful daily attention to fluid intake, salt restriction, and body weight helps catch fluid retention early, before symptoms flare.